Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bionovo has initiated the Phase I clinical trial evaluating the safety of two doses of Menerba in postmenopausal women for the treatment of menopausal hot flushes.
Subscribe to our email newsletter
The Phase 1, open-label, randomised, clinical trial will be conducted at three clinical sites in Northern California, US.
The study will enroll 40 postmenopausal women between the ages of 40 and 65 years, who will be randomised to one of two doses of Menerba and treated for 28 days.
The primary goal of the study is to evaluate the safety of two doses MF101 after 4 weeks of treatment.
Menerba is an estrogen receptor beta (ER-b) selective drug manufactured from botanical sources, designed for the treatment of hot flushes associated with menopause.